These differences in therapies reflect a change in institutional practice around 2009 to preferentially use combination therapy with IC/HMA + TKI, rather than TKI alone, for patients with CML-MBP. Here, MBP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.